Online inquiry

IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15229MR)

This product GTTS-WQ15229MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15229MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14187MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ13652MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ9570MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ5306MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ6576MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ3289MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ1268MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ8139MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW